During the COVID-19 emergency, the Food and Drug Administration will not take action in certain circumstances against a registered outsourcing facility for compounding certain drugs to treat hospitalized patients with COVID-19; using a bulk drug substance not on the 503B bulk list; or not meeting current good manufacturing process requirements, the agency announced today.

“Many hospitals are currently experiencing difficulties accessing FDA-approved drug products used for patients with COVID-19,” the agency said. “…[I]n light of unprecedented disruptions to, and demands on, the global pharmaceutical supply chain as a result of the COVID-19 pandemic, and in order to respond to evolving regional conditions, additional flexibility is temporarily needed to ensure that treatment options are available when hospitals are unable to obtain FDA-approved drugs used for hospitalized patients with COVID-19."

Related News Articles

Perspective
One important learning from the two-and-a-half-year COVID-19 pandemic is that the public health emergency (PHE) waivers made an enormous difference for…
Headline
Children infected with COVID-19 are at higher risk afterwards for certain symptoms or conditions, according to a study released today by the Centers for…
Headline
As directed by President Biden in April, the Department of Health and Human Services today released a national plan for researching the long-term effects…
Headline
Inpatient and outpatient prospective payment system hospitals, inpatient psychiatric facilities and PPS-exempt cancer hospitals have until Aug. 30 to preview…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…
Headline
The Department of Health and Human Services has agreed to purchase 66 million doses of Moderna’s omicron-specific COVID-19 vaccine booster for use this fall if…